In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate

Abstract

Sodium rutin sulfate (SRS) is a sulfated rutin modified from the natural flavonol glycoside rutin. Here, we investigated its in vitro anti-HIV and -HSV activities and its cytotoxic profile. Fifty percent inhibitory concentration (IC 50) values of SRS against HIV-1 X4 virus IIIB, HIV-1 R5 isolates Ada-M and Ba-L were 2.3 ± 0.2, 4.5 ± 2.0 and 8.5 ± 3.8 μM with a selectivity index (SI) of 563, 575 and 329, respectively. Its IC 50 against primary R5 HIV-1 isolate from Yunnan province in China was 13.1 ± 5.5 μM, with a SI of 197. In contrast, unsulfated rutin had no activity against any of the HIV-1 isolates tested. Further study indicated that SRS blocked viral entry and virus–cell fusion likely through interacting with the HIV-1 envelope glycoprotein. SRS also demonstrated some activity against human herpes simplex virus (HSV) with an IC 50 of 88.3 ± 0.1 μM and a SI of 30. The 50% cytotoxicity concentration (CC 50) of SRS was >3.0 mM, as determined in human genital ME180, HeLa and primary human foreskin fibroblast cells. Minimum inhibitory concentration of SRS for vaginal lactobacilli was >3.0 mM. These results collectively indicate that SRS represents a novel candidate for anti-HIV-1/HSV microbicide development.